Sponsor Deadline:
Letter of Intent Deadline:
Sponsor:
UI Contact:
Updated Date:
ProposalCentral link https://proposalcentral.com/grantopportunities.asp?GMID=170
For this funding opportunity, hard-to-treat cancer is defined as 5-year survival less than 70% in an individual cancer (e.g. osteosarcoma, AML, DIPG), in a cancer with unfavorable behavior (e.g. relapse or metastasis), or in a molecular defined subtype (e.g. MLL rearranged leukemia, PAX3-FOXO1 rearranged RMS). Cancers with survival <70% in demographic groups defined by age, sex, or race/ethnicity may also qualify if a biologic hypothesis is being pursued. Applicants must demonstrate that the cancer(s) they propose to study is consistent with this definition of "hard-to-treat" and with the scientific literature.